Infusions of AP5 into the basolateral amygdala impair the formation, but not the expression, of step-down inhibitory avoidance

We evaluated the effects of infusions of the NMDA receptor antagonist D,L-2-amino-5-phosphonopentanoic acid (AP5) into the basolateral nucleus of the amygdala (BLA) on the formation and expression of memory for inhibitory avoidance. Adult male Wistar rats (215-300 g) were implanted under thionembutal anesthesia (30 mg/kg, ip) with 9.0-mm guide cannulae aimed 1.0 mm above the BLA. Bilateral infusions of AP5 (5.0 µg) were given 10 min prior to training, immediately after training, or 10 min prior to testing in a step-down inhibitory avoidance task (0.3 mA footshock, 24-h interval between training and the retention test session). Both pre- and post-training infusions of AP5 blocked retention test performance. When given prior to the test, AP5 did not affect retention. AP5 did not affect training performance, and a control experiment showed that the impairing effects were not due to alterations in footshock sensitivity. The results suggest that NMDA receptor activation in the BLA is involved in the formation, but not the expression, of memory for inhibitory avoidance in rats. However, the results do not necessarily imply that the role of NMDA receptors in the BLA is to mediate long-term storage of fear-motivated memory within the amygdala.

Involvement of hippocampal NMDA receptors in retention of shuttle avoidance conditioning in rats

The purpose of this research was to evaluate the role of hippocampal N-methyl-D-aspartate (NMDA) receptors in acquisition and consolidation of memory during shuttle avoidance conditioning in rats. Adult male Wistar rats were surgically implanted with cannulae aimed at the CA1 area of the dorsal hippocampus. After recovery from surgery, animals were trained and tested in a shuttle avoidance apparatus (30 trials, 0.5-mA footshock, 24-h training-test interval). Immediately before or immediately after training, animals received a bilateral intrahippocampal 0.5-µl infusion containing 5.0 µg of the NMDA competitive receptor antagonist aminophosphonopentanoic acid (AP5) or vehicle (phosphate-buffered saline, pH 7.4). Infusion duration was 2 min per side. Pre-training infusion of AP5 impaired retention test performance (mean Ý SEM number of conditioned responses (CRs) during retention test session was 16.47 Ý 1.78 in the vehicle group and 9.93 Ý 1.59 in the AP5 group; P<0.05). Post-training infusion of AP5 did not affect retention (mean Ý SEM number of conditioned responses during retention test session was 18.46 Ý 1.94 in the vehicle group and 20.42 Ý 2.38 in the AP5 group; P>0.10). This impairment could not be attributed to an effect on acquisition, motor activity or footshock sensitivity since AP5 affected neither training session performance measured by the number of CRs nor the number of intertrial crossings during the training session. These data suggest that NMDA receptors in the hippocampus are critical for retention of shuttle avoidance conditioning, in agreement with previous evidence showing a role of NMDA receptors in fear memory

Evidence that similar neurotransmitter mechanisms in amygdala, hippocampus and medial septum regulate memory consolidation of avoidance behavior in rats

A injeçäo de ácido DL-amino-5-fosfonopentanóico (AP5) ou escopolamina na amígdala, no septo medial ou no hipocampo, imediatamente após o treino, causa amnésia retrógrada para um aprendizado de esquiva inibitória em ratos. A picrotoxina, no entanto, causa facilitaçäo retrógrada da memória e bloqueia o efeito do AP5 e da escopolamina. O timolol näo tem efeito próprio mas cancela as açöes da picrotoxina. O AP5 é um antagonista de receptores a N-metil-D- aspartato (NMDA) dos aminoácidos excitatórios; a escopolamina é um antagonista dos receptores colinérgicos muscarínicos; a picrotoxina bloqueia o canal de cloro estimulado pelos receptores GABA-A; e o timolol é um antagonista dos ß adrenoreceptores. Os resultados indicam que, na amígdala, no septo medial e no hipocampo, receptores NMDA e muscarínicos säo necessários para a consolidaçäo da memória, receptores GABA-A inibem a açäo dos anteriores, e receptores ß noradrenérgicos modulam a açäo dos receptores GABA-A. A amígdala, o septo medial e o hipocampo operam de forma näo redundante na consolidaçäo da memória

Kynurenate and 2-amino-5-phosphonovalerate alter the spinal seizures evoked by sudden cooling of toad isolated cords

El esfriamiento brusco de la médula espinal aislada de sapos induce una convulsión característica en los miembros posteriores. En este trabajo, el kinurenato (KYN), un antagonista no competitivo de los receptores N-metil-D-aspartato (NMDA) y el 20amino-5-fosfonovalerato (APV), un antagonista competitivo de los receptores NMDA, fueron ensayados en el patrón, la latencia y la duración de esta convulsión espinal. APV, 1,3-2,5 mmol/Kg and KYN, 2,6 mmol/Kg, inhibieron la fase tónica de esta convulsión y prolongaron la duración de la fase clónica después de la administración intralinfática (i.l.). El mismo efecto fue observado después de la inyección intratecal de dosis de 10 ó 20 µmol/20 µl de cada droga. La fase clónica fue maracadamente atenuada por KYN a dosis altas de 5.3 ó 10.6 mmol/Kg, i.l., sugiriendo que receptores del tipo no NMDA podrían tener alguna mediciación en la generación de dicha fase. Ambos antagonistas retardaron el comienzo de las convulsiones, indicando que la activación de los receptores NMDA están probablemente involucrados en el comienzo de este tipo de convulsiones. Este modelo espinal podría ser una técnica útil para el ensayo de otros antagonistas de amino ácidos excitatorios